AAPL332.27+5.70 (+1.75%) ▲|ABBV257.12+2.12 (+0.83%) ▲|ABT101.95-1.41 (-1.36%) ▼|ACN183.90+5.99 (+3.37%) ▲|ADBE252.23+3.40 (+1.37%) ▲|AMAT456.49+2.48 (+0.55%) ▲|AMD516.13+12.53 (+2.49%) ▲|AMGN377.35-5.12 (-1.34%) ▼|AMT177.85+4.87 (+2.82%) ▲|AMZN256.78+4.89 (+1.94%) ▲|AVGO361.99+1.16 (+0.32%) ▲|AXP324.69+3.98 (+1.24%) ▲|BA210.45+5.65 (+2.76%) ▲|BAC62.69+0.13 (+0.21%) ▲|BKNG173.92+0.01 (+0.01%) ▲|BLK1,079.65+17.25 (+1.62%) ▲|BMY63.64-0.11 (-0.17%) ▼|BNY162.66+0.07 (+0.04%) ▲|BRK-B510.37+3.37 (+0.66%) ▲|C138.82+0.32 (+0.23%) ▲|CAT818.57+13.57 (+1.69%) ▲|CL86.80-1.10 (-1.25%) ▼|CMCSA25.20+0.03 (+0.12%) ▲|COF208.30+1.19 (+0.57%) ▲|COP137.35+0.31 (+0.23%) ▲|COST904.77+2.39 (+0.26%) ▲|CRM247.72+4.72 (+1.94%) ▲|CSCO112.13+4.69 (+4.37%) ▲|CVS94.66-0.63 (-0.66%) ▼|CVX214.06+1.30 (+0.61%) ▲|DE675.74-2.20 (-0.32%) ▼|DHR200.14-0.39 (-0.19%) ▼|DIS106.55+0.73 (+0.69%) ▲|DUK119.42+0.05 (+0.04%) ▲|EMR152.19+3.82 (+2.57%) ▲|FDX311.99+0.19 (+0.06%) ▲|GD355.90+1.65 (+0.47%) ▲|GE323.66-0.49 (-0.15%) ▼|GEV957.27+33.36 (+3.61%) ▲|GILD143.72-1.09 (-0.75%) ▼|GM85.62-0.50 (-0.58%) ▼|GOOG335.45+5.06 (+1.53%) ▲|GOOGL338.50+5.90 (+1.77%) ▲|GS1,029.18+9.41 (+0.92%) ▲|HD308.74+3.05 (+1.00%) ▲|HON202.36+0.18 (+0.09%) ▲|IBM243.29+9.27 (+3.96%) ▲|INTC102.94+2.62 (+2.61%) ▲|INTU321.57+8.80 (+2.81%) ▲|ISRG369.15+8.69 (+2.41%) ▲|JNJ265.58-0.77 (-0.29%) ▼|JPM356.23+2.67 (+0.76%) ▲|KO88.29+0.46 (+0.52%) ▲|LIN466.22+4.60 (+1.00%) ▲|LLY1,115.70-7.30 (-0.65%) ▼|LMT524.19-5.93 (-1.12%) ▼|LOW196.82+0.23 (+0.12%) ▲|LRCX298.22+0.21 (+0.07%) ▲|MA569.19+3.82 (+0.68%) ▲|MCD252.53-0.52 (-0.21%) ▼|MDLZ62.44-0.03 (-0.05%) ▼|MDT90.96-0.66 (-0.72%) ▼|META648.03+3.65 (+0.57%) ▲|MMM164.97+2.11 (+1.30%) ▲|MO68.98+0.19 (+0.28%) ▲|MRK143.93-0.78 (-0.54%) ▼|MS214.38+1.72 (+0.81%) ▲|MSFT495.63+3.19 (+0.65%) ▲|MU975.26-2.15 (-0.22%) ▼|NEE82.31-0.13 (-0.16%) ▼|NFLX77.40+1.39 (+1.83%) ▲|NKE36.80+0.18 (+0.49%) ▲|NOW132.53+1.36 (+1.04%) ▲|NVDA218.29-0.07 (-0.03%) ▼|ORCL150.28-2.66 (-1.74%) ▼|PEP136.32-0.33 (-0.24%) ▼|PFE27.72+0.07 (+0.25%) ▲|PG145.27+2.30 (+1.61%) ▲|PLTR167.23+1.37 (+0.83%) ▲|PM191.06+1.29 (+0.68%) ▲|QCOM181.97+5.09 (+2.88%) ▲|RTX197.68-0.44 (-0.22%) ▼|SBUX98.74-0.48 (-0.48%) ▼|SCHW107.25-0.08 (-0.07%) ▼|SO87.17-0.58 (-0.66%) ▼|SPG204.83+0.16 (+0.08%) ▲|T26.06+0.51 (+2.00%) ▲|TMO609.82+6.64 (+1.10%) ▲|TMUS182.33+5.17 (+2.92%) ▲|TSLA365.44+1.88 (+0.52%) ▲|TXN268.70+9.88 (+3.82%) ▲|UBER71.67-0.89 (-1.23%) ▼|UNH379.09-9.19 (-2.37%) ▼|UNP284.40-1.38 (-0.48%) ▼|UPS100.28+0.31 (+0.31%) ▲|USB62.84+0.43 (+0.69%) ▲|V370.45+3.24 (+0.88%) ▲|VZ50.61+0.64 (+1.28%) ▲|WFC90.29+0.84 (+0.94%) ▲|WMT107.15+1.42 (+1.34%) ▲|XOM165.99+0.76 (+0.46%) ▲|AAPL332.27+5.70 (+1.75%) ▲|ABBV257.12+2.12 (+0.83%) ▲|ABT101.95-1.41 (-1.36%) ▼|ACN183.90+5.99 (+3.37%) ▲|ADBE252.23+3.40 (+1.37%) ▲|AMAT456.49+2.48 (+0.55%) ▲|AMD516.13+12.53 (+2.49%) ▲|AMGN377.35-5.12 (-1.34%) ▼|AMT177.85+4.87 (+2.82%) ▲|AMZN256.78+4.89 (+1.94%) ▲|AVGO361.99+1.16 (+0.32%) ▲|AXP324.69+3.98 (+1.24%) ▲|BA210.45+5.65 (+2.76%) ▲|BAC62.69+0.13 (+0.21%) ▲|BKNG173.92+0.01 (+0.01%) ▲|BLK1,079.65+17.25 (+1.62%) ▲|BMY63.64-0.11 (-0.17%) ▼|BNY162.66+0.07 (+0.04%) ▲|BRK-B510.37+3.37 (+0.66%) ▲|C138.82+0.32 (+0.23%) ▲|CAT818.57+13.57 (+1.69%) ▲|CL86.80-1.10 (-1.25%) ▼|CMCSA25.20+0.03 (+0.12%) ▲|COF208.30+1.19 (+0.57%) ▲|COP137.35+0.31 (+0.23%) ▲|COST904.77+2.39 (+0.26%) ▲|CRM247.72+4.72 (+1.94%) ▲|CSCO112.13+4.69 (+4.37%) ▲|CVS94.66-0.63 (-0.66%) ▼|CVX214.06+1.30 (+0.61%) ▲|DE675.74-2.20 (-0.32%) ▼|DHR200.14-0.39 (-0.19%) ▼|DIS106.55+0.73 (+0.69%) ▲|DUK119.42+0.05 (+0.04%) ▲|EMR152.19+3.82 (+2.57%) ▲|FDX311.99+0.19 (+0.06%) ▲|GD355.90+1.65 (+0.47%) ▲|GE323.66-0.49 (-0.15%) ▼|GEV957.27+33.36 (+3.61%) ▲|GILD143.72-1.09 (-0.75%) ▼|GM85.62-0.50 (-0.58%) ▼|GOOG335.45+5.06 (+1.53%) ▲|GOOGL338.50+5.90 (+1.77%) ▲|GS1,029.18+9.41 (+0.92%) ▲|HD308.74+3.05 (+1.00%) ▲|HON202.36+0.18 (+0.09%) ▲|IBM243.29+9.27 (+3.96%) ▲|INTC102.94+2.62 (+2.61%) ▲|INTU321.57+8.80 (+2.81%) ▲|ISRG369.15+8.69 (+2.41%) ▲|JNJ265.58-0.77 (-0.29%) ▼|JPM356.23+2.67 (+0.76%) ▲|KO88.29+0.46 (+0.52%) ▲|LIN466.22+4.60 (+1.00%) ▲|LLY1,115.70-7.30 (-0.65%) ▼|LMT524.19-5.93 (-1.12%) ▼|LOW196.82+0.23 (+0.12%) ▲|LRCX298.22+0.21 (+0.07%) ▲|MA569.19+3.82 (+0.68%) ▲|MCD252.53-0.52 (-0.21%) ▼|MDLZ62.44-0.03 (-0.05%) ▼|MDT90.96-0.66 (-0.72%) ▼|META648.03+3.65 (+0.57%) ▲|MMM164.97+2.11 (+1.30%) ▲|MO68.98+0.19 (+0.28%) ▲|MRK143.93-0.78 (-0.54%) ▼|MS214.38+1.72 (+0.81%) ▲|MSFT495.63+3.19 (+0.65%) ▲|MU975.26-2.15 (-0.22%) ▼|NEE82.31-0.13 (-0.16%) ▼|NFLX77.40+1.39 (+1.83%) ▲|NKE36.80+0.18 (+0.49%) ▲|NOW132.53+1.36 (+1.04%) ▲|NVDA218.29-0.07 (-0.03%) ▼|ORCL150.28-2.66 (-1.74%) ▼|PEP136.32-0.33 (-0.24%) ▼|PFE27.72+0.07 (+0.25%) ▲|PG145.27+2.30 (+1.61%) ▲|PLTR167.23+1.37 (+0.83%) ▲|PM191.06+1.29 (+0.68%) ▲|QCOM181.97+5.09 (+2.88%) ▲|RTX197.68-0.44 (-0.22%) ▼|SBUX98.74-0.48 (-0.48%) ▼|SCHW107.25-0.08 (-0.07%) ▼|SO87.17-0.58 (-0.66%) ▼|SPG204.83+0.16 (+0.08%) ▲|T26.06+0.51 (+2.00%) ▲|TMO609.82+6.64 (+1.10%) ▲|TMUS182.33+5.17 (+2.92%) ▲|TSLA365.44+1.88 (+0.52%) ▲|TXN268.70+9.88 (+3.82%) ▲|UBER71.67-0.89 (-1.23%) ▼|UNH379.09-9.19 (-2.37%) ▼|UNP284.40-1.38 (-0.48%) ▼|UPS100.28+0.31 (+0.31%) ▲|USB62.84+0.43 (+0.69%) ▲|V370.45+3.24 (+0.88%) ▲|VZ50.61+0.64 (+1.28%) ▲|WFC90.29+0.84 (+0.94%) ▲|WMT107.15+1.42 (+1.34%) ▲|XOM165.99+0.76 (+0.46%) ▲|
22.7 C
New York
Sunday, September 13, 2026

Tag: research

newssourceFORcompanyinformationcontent1releasesmarket

Elkedonia closes EUR 11 million seed round to advance neuroplastogens as novel therapeutics for depression and neuropsychiatric disorders

Strasbourg, France and Charleroi, Belgium, June 11th  2025 – Elkedonia SAS, a company pioneering a novel neuroplastogen approach to develop therapeutic agents to treat depression and other neuropsychiatric condition, announced today that it has closed an oversubscribed EUR 11.25 million Seed funding round. The round was co-led by Kurma Partners, WE Life Sciences and the French Tech Seed fund managed on behalf of the French government by Bpifrance as part of France 2030, with participation from Argobio, Angelini Ventures, CARMA Fund, Capital Grand Est and Sambrinvest. Elkedonia is bringing together stakeholders from across the European ecosystem, with headquarters in Strasbourg, France and an affiliate in Charleroi, Belgium.

Angelini Ventures Invests into €11.25 Million Seed Round for Elkedonia to Advance Neuroplastogens as Novel Therapeutics for Depression and Neuropsychiatric Disorders

Investment supports the development of first-in-class, non-addictive, non-hallucinogenic molecules with a non-synaptic target, differentiated from existing drugs

MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies

MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines 
MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines

NX Belgium Opens New Logistics Base at Brussels Airport’s Brucargo Central

- Expands Services as Logistics Hub for Healthcare Industry in Europe - TOKYO, June 11, 2025 /PRNewswire/ -- Nippon Express (Belgium) NV/SA (hereinafter "NX Belgium"),...

CROSSJECT advances on the development of ZEPIZURE® Junior, its solution for epilepsy crises in children

Press release

ONWARD Medical Schedules Webcast to Provide Q1 2025 Business Update and Year-To-Date Highlights

EINDHOVEN, the Netherlands, June 11, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function and independence in people with spinal cord injury and other movement disabilities, today announces that it will host a webcast to discuss its Q1 2025 business update and year-to-date highlights.

Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics

- The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug...

Kelun-Biotech Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer

CHENGDU, China, June 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT)...

Another Milestone: Arctech Ranks World’s No. 2 in Solar Tracker Market

KUNSHAN, China, June 10, 2025 /CNW/ -- Recently, Wood Mackenzie, a world-renowned energy research firm, released its 2025 Global Solar PV Tracker Market Share...

33rd GILF Pre-Registration Open: Harnessing a Hundred-Billion-Yuan Industry to Pioneer New Lighting Trends

ZHONGSHAN, China, June 11, 2025 /PRNewswire/ -- The 33rd China (Guzhen) International Lighting Fair (GILF) will take place from October 22 to 25 at...

Whalet Joins Forces with TerraPay to Empower SMEs with Seamless Global Payouts

SINGAPORE, June 11, 2025 /PRNewswire/ -- Whalet, a leading digital payment provider, has announced a strategic partnership with TerraPay, a global money movement company,...

ROOH Officially Opens in Toronto With Focus on Health-Conscious Indian Cuisine

ROOH has officially launched in downtown Toronto, offering a health-focused Indian dining experience centered on nutrition, sustainability.

CREFC Honors Lea Overby as This Year’s Woman of Distinction and Toby Cobb as 2025’s Recipient of the Prestigious Founders Award

2025 Award Winners Announced at CREFC's Annual June Conference  NEW YORK, June 10, 2025 /PRNewswire/ -- The CRE Finance Council (CREFC) announced today that Lea Overby...

Cooper Aerobics Partners with Parker University

Cooper Aerobics announces a partnership with Parker University, bringing medically validated CooperFit™ cardiovascular fitness test to two Parker clinics.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsResearch

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers